Table 2. Response rate and disease progression.
| Clinical outcome | ES-SCLC patients (N=49) | Apatinib treatment line | ||
|---|---|---|---|---|
| Second-line (n=24) | Third-line (n=22) | ≥ Forth-line (n=3) | ||
| CR, n (%) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.0) |
| PR, n (%) | 7 (14.3) | 3 (12.5) | 4 (18.2) | 0 (0.0) |
| SD, n (%) | 32 (65.3) | 18 (75.0) | 11 (50.0) | 3 (100.0) |
| PD, n (%) | 10 (20.4) | 3 (12.5) | 7 (31.8) | 0 (0.0) |
| ORR (%), median (95% CI) | 14.3 (4.5–24.1) | 12.5 (0.0–25.7) | 18.2 (2.01–34.3) | 0 (0.0) |
| DCR (%), median (95% CI) | 79.6 (68.3–90.9) | 87.5 (74.3–100) | 68.2 (48.7–87.6) | 100.0 |
| PFS (months), median (95% CI) | 5.6 (3.4–6.5) | 6.1 (2.6–7.6) | 5.4 (1.8–6.5) | 3.6 (3.2–12.0) |
| OS (months), median (95% CI) | 11.2 (7.5–24.0) | 12.0 (7.9–NR) | 7.5 (5.6–24.0) | 11.2 (7.1–14.1) |
ES-SCLC, extensive stage small cell lung cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; NR, not reached; CI, confidence interval.